Prognostic factors in the nonsurgical treatment of esophageal carcinoma with radiotherapy or radiochemotherapy

The importance of pretreatment hemoglobin levels

Dirk Rades, Steven E. Schild, Roja Bahrehmand, Oliver Zschenker, Winfried A. Alberti, Volker R. Rudat

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

BACKGROUND. The current study was performed to evaluate prognostic factors for overall survival (OS), distant metastasis (DM), and local failure (LF) in patients with Stage II/III esophageal carcinoma. METHODS. The following potential prognostic factors were retrospectively investigated in 124 patients treated with radiotherapy (RT) alone or with radiochemotherapy: age, gender, performance status, tumor location, tumor length, histology, histologic grade, T classification, N classification, International Union Against Cancer stage, chemotherapy, RT dose, and pre-RT hemoglobin level. RESULTS. Using univariate analysis (Kaplan-Meier method), pre-RT hemoglobin level, RT dose, tumor length, chemotherapy, and performance status were significantly associated with OS. Hemoglobin levels of 12.1-14.0 g/dL were associated with the best OS, followed by ≥ 14.1 g/dL and ≤ 12.0 g/dL. DM was significantly influenced by tumor length, RT dose, N classification, and performance status. LF was significantly influenced by pre-RT hemoglobin level, RT dose, and tumor length. Using multivariate analysis (Cox proportional hazard model), pre-RT hemoglobin maintained significance for OS (P < 0.001) and LF (P < 0.001), RT dose for OS (P = 0.001), DM (P = 0.031), and LF (P < 0.001), tumor length for OS (P = 0.003), DM (P = 0.017), and LF (P = 0.033), and chemotherapy for OS (P = 0.027). N classification was of borderline significance for DM (P = 0.054). Performance status lost significance for OS (P = 0.73) and LF (P = 0.22). CONCLUSIONS. The strongest predictors for outcome in Stage II/III esophageal carcinoma were RT dose, tumor length, pre-RT hemoglobin level, and chemotherapy. The pre-RT hemoglobin level was an independent prognostic factor significantly associated with OS and LF. A hemoglobin level of 12.1-14 g/dL resulted in a better prognosis than hemoglobin levels ≥ 14 g/dL and ≤ 12 g/dL.

Original languageEnglish (US)
Pages (from-to)1740-1746
Number of pages7
JournalCancer
Volume103
Issue number8
DOIs
StatePublished - Apr 15 2005

Fingerprint

Chemoradiotherapy
Hemoglobins
Radiotherapy
Carcinoma
Survival
Neoplasm Metastasis
Therapeutics
Neoplasms
Drug Therapy
Kaplan-Meier Estimate
Proportional Hazards Models
Histology
Multivariate Analysis

Keywords

  • Esophageal carcinoma
  • Pretreatment hemoglobin level
  • Prognostic factors
  • Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prognostic factors in the nonsurgical treatment of esophageal carcinoma with radiotherapy or radiochemotherapy : The importance of pretreatment hemoglobin levels. / Rades, Dirk; Schild, Steven E.; Bahrehmand, Roja; Zschenker, Oliver; Alberti, Winfried A.; Rudat, Volker R.

In: Cancer, Vol. 103, No. 8, 15.04.2005, p. 1740-1746.

Research output: Contribution to journalArticle

Rades, Dirk ; Schild, Steven E. ; Bahrehmand, Roja ; Zschenker, Oliver ; Alberti, Winfried A. ; Rudat, Volker R. / Prognostic factors in the nonsurgical treatment of esophageal carcinoma with radiotherapy or radiochemotherapy : The importance of pretreatment hemoglobin levels. In: Cancer. 2005 ; Vol. 103, No. 8. pp. 1740-1746.
@article{b1905a9defd1448b9b0dcde08d2e64ed,
title = "Prognostic factors in the nonsurgical treatment of esophageal carcinoma with radiotherapy or radiochemotherapy: The importance of pretreatment hemoglobin levels",
abstract = "BACKGROUND. The current study was performed to evaluate prognostic factors for overall survival (OS), distant metastasis (DM), and local failure (LF) in patients with Stage II/III esophageal carcinoma. METHODS. The following potential prognostic factors were retrospectively investigated in 124 patients treated with radiotherapy (RT) alone or with radiochemotherapy: age, gender, performance status, tumor location, tumor length, histology, histologic grade, T classification, N classification, International Union Against Cancer stage, chemotherapy, RT dose, and pre-RT hemoglobin level. RESULTS. Using univariate analysis (Kaplan-Meier method), pre-RT hemoglobin level, RT dose, tumor length, chemotherapy, and performance status were significantly associated with OS. Hemoglobin levels of 12.1-14.0 g/dL were associated with the best OS, followed by ≥ 14.1 g/dL and ≤ 12.0 g/dL. DM was significantly influenced by tumor length, RT dose, N classification, and performance status. LF was significantly influenced by pre-RT hemoglobin level, RT dose, and tumor length. Using multivariate analysis (Cox proportional hazard model), pre-RT hemoglobin maintained significance for OS (P < 0.001) and LF (P < 0.001), RT dose for OS (P = 0.001), DM (P = 0.031), and LF (P < 0.001), tumor length for OS (P = 0.003), DM (P = 0.017), and LF (P = 0.033), and chemotherapy for OS (P = 0.027). N classification was of borderline significance for DM (P = 0.054). Performance status lost significance for OS (P = 0.73) and LF (P = 0.22). CONCLUSIONS. The strongest predictors for outcome in Stage II/III esophageal carcinoma were RT dose, tumor length, pre-RT hemoglobin level, and chemotherapy. The pre-RT hemoglobin level was an independent prognostic factor significantly associated with OS and LF. A hemoglobin level of 12.1-14 g/dL resulted in a better prognosis than hemoglobin levels ≥ 14 g/dL and ≤ 12 g/dL.",
keywords = "Esophageal carcinoma, Pretreatment hemoglobin level, Prognostic factors, Radiotherapy",
author = "Dirk Rades and Schild, {Steven E.} and Roja Bahrehmand and Oliver Zschenker and Alberti, {Winfried A.} and Rudat, {Volker R.}",
year = "2005",
month = "4",
day = "15",
doi = "10.1002/cncr.20952",
language = "English (US)",
volume = "103",
pages = "1740--1746",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Prognostic factors in the nonsurgical treatment of esophageal carcinoma with radiotherapy or radiochemotherapy

T2 - The importance of pretreatment hemoglobin levels

AU - Rades, Dirk

AU - Schild, Steven E.

AU - Bahrehmand, Roja

AU - Zschenker, Oliver

AU - Alberti, Winfried A.

AU - Rudat, Volker R.

PY - 2005/4/15

Y1 - 2005/4/15

N2 - BACKGROUND. The current study was performed to evaluate prognostic factors for overall survival (OS), distant metastasis (DM), and local failure (LF) in patients with Stage II/III esophageal carcinoma. METHODS. The following potential prognostic factors were retrospectively investigated in 124 patients treated with radiotherapy (RT) alone or with radiochemotherapy: age, gender, performance status, tumor location, tumor length, histology, histologic grade, T classification, N classification, International Union Against Cancer stage, chemotherapy, RT dose, and pre-RT hemoglobin level. RESULTS. Using univariate analysis (Kaplan-Meier method), pre-RT hemoglobin level, RT dose, tumor length, chemotherapy, and performance status were significantly associated with OS. Hemoglobin levels of 12.1-14.0 g/dL were associated with the best OS, followed by ≥ 14.1 g/dL and ≤ 12.0 g/dL. DM was significantly influenced by tumor length, RT dose, N classification, and performance status. LF was significantly influenced by pre-RT hemoglobin level, RT dose, and tumor length. Using multivariate analysis (Cox proportional hazard model), pre-RT hemoglobin maintained significance for OS (P < 0.001) and LF (P < 0.001), RT dose for OS (P = 0.001), DM (P = 0.031), and LF (P < 0.001), tumor length for OS (P = 0.003), DM (P = 0.017), and LF (P = 0.033), and chemotherapy for OS (P = 0.027). N classification was of borderline significance for DM (P = 0.054). Performance status lost significance for OS (P = 0.73) and LF (P = 0.22). CONCLUSIONS. The strongest predictors for outcome in Stage II/III esophageal carcinoma were RT dose, tumor length, pre-RT hemoglobin level, and chemotherapy. The pre-RT hemoglobin level was an independent prognostic factor significantly associated with OS and LF. A hemoglobin level of 12.1-14 g/dL resulted in a better prognosis than hemoglobin levels ≥ 14 g/dL and ≤ 12 g/dL.

AB - BACKGROUND. The current study was performed to evaluate prognostic factors for overall survival (OS), distant metastasis (DM), and local failure (LF) in patients with Stage II/III esophageal carcinoma. METHODS. The following potential prognostic factors were retrospectively investigated in 124 patients treated with radiotherapy (RT) alone or with radiochemotherapy: age, gender, performance status, tumor location, tumor length, histology, histologic grade, T classification, N classification, International Union Against Cancer stage, chemotherapy, RT dose, and pre-RT hemoglobin level. RESULTS. Using univariate analysis (Kaplan-Meier method), pre-RT hemoglobin level, RT dose, tumor length, chemotherapy, and performance status were significantly associated with OS. Hemoglobin levels of 12.1-14.0 g/dL were associated with the best OS, followed by ≥ 14.1 g/dL and ≤ 12.0 g/dL. DM was significantly influenced by tumor length, RT dose, N classification, and performance status. LF was significantly influenced by pre-RT hemoglobin level, RT dose, and tumor length. Using multivariate analysis (Cox proportional hazard model), pre-RT hemoglobin maintained significance for OS (P < 0.001) and LF (P < 0.001), RT dose for OS (P = 0.001), DM (P = 0.031), and LF (P < 0.001), tumor length for OS (P = 0.003), DM (P = 0.017), and LF (P = 0.033), and chemotherapy for OS (P = 0.027). N classification was of borderline significance for DM (P = 0.054). Performance status lost significance for OS (P = 0.73) and LF (P = 0.22). CONCLUSIONS. The strongest predictors for outcome in Stage II/III esophageal carcinoma were RT dose, tumor length, pre-RT hemoglobin level, and chemotherapy. The pre-RT hemoglobin level was an independent prognostic factor significantly associated with OS and LF. A hemoglobin level of 12.1-14 g/dL resulted in a better prognosis than hemoglobin levels ≥ 14 g/dL and ≤ 12 g/dL.

KW - Esophageal carcinoma

KW - Pretreatment hemoglobin level

KW - Prognostic factors

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=16844385108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16844385108&partnerID=8YFLogxK

U2 - 10.1002/cncr.20952

DO - 10.1002/cncr.20952

M3 - Article

VL - 103

SP - 1740

EP - 1746

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -